Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 19, 2017BMC OphthalmologyOpen Access

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

FZFocke ZiemssenLeipzig UniversityNFNicolas FeltgenUniversity Hospital of BaselFHFG. Holz

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ziemssen et al. (2017) studied this question.

synapsesocial.com/papers/6aa17978ff9f1d2cd5b572c2https://doi.org/10.1186/s12886-017-0401-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Drug Policy for an Aging Population — The European Medicines Agency's Geriatric Medicines Strategy2012 · 134 citations
  2. 2Global Prevalence and Major Risk Factors of Diabetic Retinopathy2012 · 5,053 citations
  3. 3Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial2013 · 758 citations